1. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Issue 10192 (6th July 2019) Authors: Moreau, Philippe; Attal, Michel; Hulin, Cyrille; Arnulf, Bertrand; Belhadj, Karim; Benboubker, Lotfi; Béné, Marie C; Broijl, Annemiek; Caillon, Hélène; Caillot, Denis; Corre, Jill; Delforge, Michel; Dejoie, Thomas; Doyen, Chantal; Facon, Thierry; Sonntag, Cécile; Fontan, Jean; Garderet, Laurent; ... Journal: Lancet Issue: Volume 394:Issue 10192(2019) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice. Issue 12 (29th December 2022) Authors: Delforge, Michel; Vekemans, Marie-Christiane; Depaus, Julien; Meuleman, Nathalie; Van de Velde, Ann; Vande Broek, Isabelle; Vandervennet, Sophie; Van Hoorenbeeck, Sandra; Moorkens, Evelien; Strens, Danielle; Diels, Joris; Ghilotti, Francesca; Haefliger, Benjamin; Dalhuisen, Sander; Deraedt, Willi... Journal: HemaSphere Issue: Volume 6:Issue 12(2022) Page Start: e813 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Issue 10297 (24th July 2021) Authors: Berdeja, Jesus G; Madduri, Deepu; Usmani, Saad Z; Jakubowiak, Andrzej; Agha, Mounzer; Cohen, Adam D; Stewart, A Keith; Hari, Parameswaran; Htut, Myo; Lesokhin, Alexander; Deol, Abhinav; Munshi, Nikhil C; O'Donnell, Elizabeth; Avigan, David; Singh, Indrajeet; Zudaire, Enrique; Yeh, Tzu-Min; Allred... Journal: Lancet Issue: Volume 398:Issue 10297(2021) Page Start: 314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study. Issue 12 (December 2022) Authors: Martin, Thomas; Lin, Yi; Agha, Mounzer; Cohen, Adam D; Htut, Myo; Stewart, A Keith; Hari, Parameswaran; Berdeja, Jesus G; Usmani, Saad Z; Yeh, Tzu-Min; Olyslager, Yunsi; Goldberg, Jenna D; Schecter, Jordan M; Madduri, Deepu; Jackson, Carolyn C; Deraedt, William; Gries, Katharine S; Fastenau, John... Journal: Lancet Issue: Volume 9:Issue 12(2022) Page Start: e897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. (3rd October 2021) Authors: Martin, Tom; Usmani, Saad Z.; Schecter, Jordan M.; Vogel, Martin; Jackson, Carolyn C.; Deraedt, William; Tian, Hong; Yeh, Tzu-min; Banerjee, Arnob; Pacaud, Lida; Garrett, Ashraf; Haltner, Anja; Cameron, Chris; Van Sanden, Suzy; Diels, Joris; Valluri, Satish; Samjoo, Imtiaz A. Journal: Current medical research and opinion Issue: Volume 37:Number 10(2021) Page Start: 1779 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. Issue 3 (23rd February 2020) Authors: Mateos, Maria-Victoria; San-Miguel, Jesus; Goldschmidt, Hartmut; Sonneveld, Pieter; Dimopoulos, Meletios A.; Heeg, Bart; Hashim, Mahmoud; Deraedt, William; Hu, Peter; Lam, Annette; He, Jianming Journal: Leukemia & lymphoma Issue: Volume 61:Issue 3(2020) Page Start: 680 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. (2nd January 2023) Authors: Martin, Tom; Usmani, Saad Z.; Schecter, Jordan M.; Roccia, Tito; Jackson, Carolyn C.; Deraedt, William; Yeh, Tzu-min; Banerjee, Arnob; Pacaud, Lida; Garrett, Ashraf; Bartlett, Meaghan; Haltner, Anja; Van Sanden, Suzy; Diels, Joris; Valluri, Satish; Samjoo, Imtiaz A. Journal: Current medical research and opinion Issue: Volume 39:Number 1(2023) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗